Your browser doesn't support javascript.
loading
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
O'Brien, Susan M; Byrd, John C; Hillmen, Peter; Coutre, Steven; Brown, Jennifer R; Barr, Paul M; Barrientos, Jacqueline C; Devereux, Stephen; Robak, Tadeusz; Reddy, Nishitha M; Kipps, Thomas J; Tedeschi, Alessandra; Cymbalista, Florence; Ghia, Paolo; Chang, Stephen; Ninomoto, Joi; James, Danelle F; Burger, Jan A.
Afiliação
  • O'Brien SM; Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Irvine, California.
  • Byrd JC; Department of Internal Medicine, Division of Hematology, The Ohio State University Medical Center, Columbus, Ohio.
  • Hillmen P; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
  • Coutre S; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
  • Brown JR; Department of Medicine, Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barr PM; Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, New York.
  • Barrientos JC; Department of Medicine, Division of Hematology and Medical Oncology, Hofstra Northwell School of Medicine, Hempstead, New York.
  • Devereux S; Department of Life Sciences and Medicine, Division of Cancer Studies, Kings College Hospital, London, United Kingdom.
  • Robak T; Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lódz, Poland.
  • Reddy NM; Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Kipps TJ; Department of Medicine, Division of Hematology-Oncology, UC San Diego Health, Moores Cancer Center, San Diego, California.
  • Tedeschi A; Department of Hematology, Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy.
  • Cymbalista F; Service Hematologie Biologique, Hôpital Avicenne, Université Paris 13, Bobigny, France.
  • Ghia P; Strategic Research Program in CLL, Division of Experimental Oncology, Universitè Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Chang S; Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • Ninomoto J; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • James DF; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • Burger JA; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Am J Hematol ; 94(5): 554-562, 2019 05.
Article em En | MEDLINE | ID: mdl-30767298
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article